#rare disease
Related Stories (4)
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis - Reuters
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis Reuters
October 4, 2026Scholar Rock gets first FDA nod for rare muscle-wasting disease - Reuters
Scholar Rock gets first FDA nod for rare muscle-wasting disease Reuters
September 11, 2026Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug Reuters
August 12, 2026EU regulator backs revoking Amgen's right to sell rare-disease drug - Reuters
EU regulator backs revoking Amgen's right to sell rare-disease drug Reuters
June 26, 2026Related Pages (3)
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa